Please use this identifier to cite or link to this item: http://sgc.anlis.gob.ar/handle/123456789/35
Title: Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study
Authors: Mordoh, Jose 
Kairiyama, Claudia 
Bover, Laura 
Solarolo, Elsa 
Keywords: Melanoma;Vacunas contra el Cáncer;Ganglios Linfáticos;Células Alogénicas;Argentina
Issue Date: 1997
Project: datasets
Journal: Medicina (Buenos Aires) 
Abstract: 
The incidence of melanoma is increasing rapidly, and in many cases the primary tumor is excised after metastatic spreading. In 80% of the cases, the first metastatic site is in regional lymph nodes (AJCC Stage III). After excision of these nodes, the patient is clinically disease-free, but the chances of recurrency vary between 40-80%. Thirty patients with stage III melanoma were treated in a non-randomized Phase II adjuvant trial with a vaccine consisting of a mixture of three allogeneic cell lines: IIB-MEL-J, IIB-MEL-LES and IIB-MEL-IAN (5 x 10(6) cells each). The cells were irradiated (5,000 cGy) and BCG was used as nonspecific stimulant. Before each vaccination (72 hr) the patients received cyclophosphamide (300 mg/sqm). The untreated control group was composed of 24 Stage III melanoma patients. Vaccination started within 60 days after surgery, and patients received 4 vaccinations, one every 21 days and then 1 every two months during the 1st year; 1 every three months during the 2nd year, and 1 every 6 months during the 3rd, 4th and 5th years. The treated group was composed by 19 men (63.3%) and 11 women (36.7%); average age: 47.6 +/- 14.1 years (range: 16-70 yr). The control group was composed by 18 men (75%) and 6 women (25%); average age 49.8 +/- 14.2 yr (range: 26-73 yr). The median disease free survival (DFS) calculated according to Kaplan-Meier was 7.0 months in the control group vs 20.0 months in the treated group (p < 0.001). The results of this clinical trial suggest that treatment with allogeneic cell vaccines increases DFS in stage III melanoma patients.
Description: 
Fil: Solarolo, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Microbiología; Argentina.

Fil: Mordoh, Jose. Instituto de Investigaciones Bioquímicas. Fundación Campomar; Argentina

Fil: Kairiyama, Claudia. Instituto de Investigaciones Bioquímicas. Fundación Campomar; Argentina

Fil: Bover, Laura. Instituto de Investigaciones Bioquímicas. Fundación Campomar; Argentina
URI: http://sgc.anlis.gob.ar/handle/123456789/35
http://books.google.com.ar/books?id=9WnXip7NmMQC&pg=PA421&lpg=PA421&dq=Allogeneic+cells+vaccine+increases+disease-free+survival+in+stage+III+melanoma+patients:+a+non+randomized+phase+II+study&source=bl&ots=j_vwN9CtFg&sig=xNiKSFhLqtAaxKRJUIzM4U02q4g&hl=es#v=onepage&q=Allogeneic%20cells%20vaccine%20increases%20disease-free%20survival%20in%20stage%20III%20melanoma%20patients%3A%20a%20non%20randomized%20phase%20II%20study&f=false
ISSN: 0025-7680
Rights: info:eu-repo/semantics/openAccess
Open Access
Appears in Collections:snrd
Publicaciones INPB

Files in This Item:
File Description SizeFormat
Medicina (Buenos Aires) vol57,n4,1997 421-27.pdfPDF2.89 MBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

70
checked on Mar 28, 2024

Download(s)

51
checked on Mar 28, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.